All Pharma News
UCB takes on Jazz in severe epilepsy with new Fintepla label approval

UCB takes on Jazz in severe epilepsy with new Fintepla label approval
E. Sagonowsky PHARMAPHORUM
29 Mar 2022
Share Share
Zogenix To Present New Long-term Data on FINTEPLA in Lennox-Gastaut Syndrome

Zogenix To Present New Long-term Data on FINTEPLA in Lennox-Gastaut Syndrome
GLOBENEWSWIRE
04 Mar 2022
Share Share
Zogenix Provides Corporate Update and Reports Q4 and Full-Year Financial Results

Zogenix Provides Corporate Update and Reports Q4 and Full-Year Financial Results
GLOBENEWSWIRE
28 Feb 2022
Share Share
Controversial opioid Zohydro ER pulled from the market

Controversial opioid Zohydro ER pulled from the market
Z. Brennan ENDPTS
02 Feb 2022
Share Share
UCB to buy Zogenix for nearly $2B in `first step` for M&A in 2022

UCB to buy Zogenix for nearly $2B in `first step` for M&A in 2022
B. Fidler BIOPHARMADIVE
20 Jan 2022
Share Share
Zogenix Submits NDA for FINTEPLA (Fenfluramine) in Japan

Zogenix Submits NDA for FINTEPLA (Fenfluramine) in Japan
GLOBENEWSWIRE
21 Dec 2021
Share Share
Zogenix Submits Type II Variation Application to (EMA) to the Use of FINTEPLA

Zogenix Submits Type II Variation Application to (EMA) to the Use of FINTEPLA
GLOBENEWSWIRE
20 Dec 2021
Share Share
Zogenix Reports Granting of Inducement Awards

Zogenix Reports Granting of Inducement Awards
GLOBENEWSWIRE
16 Dec 2021
Share Share
Zogenix to Host Key Opinion Leader Webinar on Thymidine Kinase MT-1621

Zogenix to Host Key Opinion Leader Webinar on Thymidine Kinase MT-1621
GLOBENEWSWIRE
01 Nov 2021
Share Share
Zogenix Submits Supplemental New Drug Application for FINTEPLA®

Zogenix Submits Supplemental New Drug Application for FINTEPLA®
GLOBENEWSWIRE
28 Sep 2021
Share Share